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Cholera is a highly infectious disease and remains a serious public health burden in Bangla-
desh. The objective of the study was to measure the private demand for oral cholera vac-
cines (OCV) in Bangladesh and to investigate the key determinants of this demand,
reflected in the household’s willingness to pay (WTP) for oral cholera vaccine.
Methods
A contingent valuation method was employed in an urban setting of Bangladesh during
December 2015 to January 2016. All respondents (N = 1051) received a description of
World Health Organization (WHO) prequalified OCV, Shanchol™. Interviews were con-
ducted with either the head of households or their spouse or a major economic contributor of
the households. Respondents were asked about how much at maximum they were willing to
pay for OCV for their own and their household members’ protection. Results are presented
as the average and median of the reported maximum WTP of the respondents with standard
deviations and 95% confidence interval. Natural log-linear regression model was employed
to examine the factors influencing participants’ WTP for OCV.
Results
About 99% of the respondents expressed WTP for OCV with a maximum mean and median
WTP per vaccination (2 doses) of US$ 2.23 and US$ 1.92 respectively. On the household
level with an average number of 4.62 members, the estimated mean WTP was US$ 10
(median: US$ 7.69) which represents the perceived demand for OCV of a household to vac-
cinate against cholera.
PLOS ONE







Citation: Sarker AR, Islam Z, Sultana M, Sheikh N,
Mahumud RA, Islam M.T, et al. (2020) Willingness
to pay for oral cholera vaccines in urban
Bangladesh. PLoS ONE 15(4): e0232600. https://
doi.org/10.1371/journal.pone.0232600
Editor: Zhifeng Gao, University of Florida, UNITED
STATES
Received: October 20, 2019
Accepted: April 17, 2020
Published: April 30, 2020
Copyright: © 2020 Sarker et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Due to ethical
restrictions related to protecting study participants’
privacy, data access is subject to an application
following icddr,b data access policy (https://www.
icddrb.org/dmdocuments/icddrb%20Data%
20Access%20Policy.pdf).Interested researchers
may contact Ms Armana Ahmed (Head, Research
Administration, icddr,b) (aahmed@icddrb.org) with
further in queries related to data access. The name
of data set is Willingness to Pay for Oral Cholera
Vaccines _Vaccine Investment Strategy (VIS).
Conclusions
The demand of vaccination further indicates that there is a potential scope for recovering a
certain portion of the expenditure of immunization program by introducing direct user fees
for future cholera vaccination in Bangladesh. Findings from this study will be useful for the
policy-makers to make decision on cost-recovery in future oral cholera vaccination pro-
grams in Bangladesh and in similar countries.
Background
Cholera remains a serious public health burden globally and especially in regions where pov-
erty and poor sanitation are prevalent [1]. Bangladesh has one of the largest burdens of
endemic cholera, with an estimated 109,052 cases each year, and approximately 66 million
people are at risk of cholera [2]. There are over 3,000–5,000 deaths annually due to cholera and
high caseloads and frequent outbreaks in the country [2,3]. The endemicity of cholera in Ban-
gladesh is demonstrated by the predictable yearly occurrence of the disease in the country’s
high-risk districts and the repetitive seasonal pattern of cholera outbreaks, in spring or
autumn, or both [4]. Indeed, cholera is increasingly becoming an urban disease, in Bangladesh
particularly for Dhaka, the capital city of Bangladesh [5]. Dhaka has also experienced massive
cholera outbreaks in the past two decades, especially during major floods in 2007 and 2009.
Indeed, residents of urban slums in Dhaka are still vulnerable to cholera infection [6,7]. To
address this problem, policy makers recognized that an effective vaccine and vaccination strat-
egy are essential for urban Bangladesh [3]. The World Health Organization (WHO) recom-
mended oral cholera vaccine (OCV) for controlling cholera outbreaks in endemic regions of
the world. In 2011 cholera was declared as a global priority at sixty-fourth World Health
Assembly with a specific role for introducing OCV [8].
The prevention of disease burden and death through vaccination is one of the most cost-
effective and public health achievements of the 20th century [9–11]. Bangladesh has experi-
enced impressive improvements in increasing immunization coverage and a significant contri-
bution to the reduction of childhood mortality. The Government of Bangladesh is the main
driver of the immunization program where private and non-governmental organizations
played strong complementary roles for vaccinating people. Urban Municipalities / City Corpo-
ration, along with local government have listed healthcare providers and established sites for
vaccination, based on mainly on the population size of the wards (lowest administrative unit).
However, introduction and sustainability of a new vaccine is still challenging in low resource
countries as the costs of new vaccines are high relative to that of traditional vaccines and thus
there is a need for prioritization [10,12]. Therefore, the financing of new vaccines represents a
major hurdle for immunization programs and its success depends on global commitment,
internal financing mechanisms and technical and managerial capacity of those countries [13].
Further, in order to scale up universal vaccination major financial commitments are often
required from the public sector as well as from other related stakeholders [14]. Additionally,
private demand for vaccine that can be purchased on the private market would give important
information about financing opportunity along with public funding.
For sustainability of an immunization program including the new vaccines, the countries
should consider allowing self-financing from internal household resources. In the other
words, charging a private domestic contribution for this new vaccine would be an option [13].
The WTP method has been proven to be a standard tool for valuation of the private demand
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for future vaccines [15]. Our overall objective of the study was to capture the WTP for new
generation OCV if available in private market of Bangladesh, considering the household per-
spectives. We additionally intended to find the determinants of demand for cholera vaccine.
As there is no current available cholera vaccines in the Expanded Program on Immunization
(EPI), estimation of demand for vaccination and its determinants are expected to be useful for
the government and policy makers to adopt long term financing strategies and design future
vaccination programs in a sustainable way by adding additional resources with a given public
budget. Therefore, this findings might be useful for the policy-makers to make decisions on
cost-recovery in future oral cholera vaccination programs in Bangladesh.
Materials and methods
Methodology
To elicit respondent’s WTP Contingent Valuation Method (CVM) was used [16]. The CVM is
a standard and accepted technique of stated preferences for capturing maximum WTP and
was originally developed in the area of valuing environmental benefits [17]. However, in the
vaccination area where the population is familiar with the potential benefit of vaccination such
as avoiding cases, economic costs, pains and suffering, CVM is particularly suitable [18]. A sys-
tematic review study indicated that CVM act as a promising tool for capturing the demand for
childhood immunization in many low-and middle income countries [19]. In the healthcare
sector, CVM is recommended if respondents know what they are paying for [18,20]. In this
study, we used open-ended bidding game techniques as it produces unbiased estimates since
no particular response is promoted [21], and produces the least conservative estimates com-
pared to other available techniques [22]. In open-ended valuation, individuals are asked to
state their willingness to pay, as in a bidding game [23], and then depending on the answer,
the bid is lowered or raised until reaching the respondent’s maximum willingness to pay. How-
ever, starting-point bias and anchor bias are often associated with the bidding game techniques
[24,25]. In order to minimize such bias, the starting bid was taken from a pretest of the house-
hold survey and in consultation with local residents. We conducted proper training on data
collection process and used open ended questions to mitigate such biases [26]. It should be
noted that some previous studies used open-ended bidding game technique arguing that such
bias was not observed on WTP outcomes [27,28].
Study settings and sample
The study was conducted under the umbrella study of Gavi funded Vaccine Investment Strat-
egy (VIS) learning agenda for oral cholera vaccine with the killed whole cell oral cholera vac-
cine, Shanchol™ (manufactured by Shantha Biotechnics, in Hyderabad, India). This study
primarily aimed to assess the preventive impact, demand, acceptability, uptake, feasibility, and
cost-effectiveness of a two-dose regimen of OCV targeting children from 1 to 14 years in high
risk urban areas (Kamrangirchar, Hazaribagh and Rayer Bazar) of Bangladesh. Phase II clinical
trials of the whole cell bivalent vaccine Shanchol™ in Vietnam and India and in Bangladesh
have shown that this vaccine is safe and immunogenic in both adults and children [29–31].
The latest WHO Fact sheet indicated that Shanchol™ gives approximately 65% protection
against cholera for up to 5 years following vaccination in endemic areas [32]. A cross sectional
household survey was conducted from December 23, 2015 to January 16, 2016 before the chol-
era vaccination trial. The sample size was drawn based on earlier study in the same country
context, it was found that 74% of respondents decided to purchase oral cholera vaccine for
their family members [33]. In this context, the following equation was applied for the sample
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Where, n = sample size to be calculated, p = proportion having the characteristic being
measured (0.74), Z = value of normal distribution at 95% confidence level (1.96), d = tolerable
standard error (0.03). We assumed at 20% non-response rate during household survey there-
fore at least 986 households were required for this survey. The households were randomly
selected from the study area, and the respondents were the household head or the major eco-
nomic contributor of the household if household head was not available.
The survey instruments
A paper-based survey instrument (questionnaire) was developed and implemented by the data
collectors under the supervision of the research team. The data collectors were pre-trained in
CVM survey according to the guidelines recommended in Whittington’s review of CV prac-
tices in developing countries [34] and the questionnaires were translated into the local lan-
guage (Bangla) in order to maintain consistency. The survey tool is validated earlier in the
context of Bangladesh [33]. The pre-test survey of the instruments was conducted in the com-
munity before the original survey to refine the language and determine respondents’ views of
possible vaccine prices to offer.
The survey instrument was approved by the Research Review Committee and the Ethical
Review Committee of the Institutional Review Board of the International Centre for Diar-
rhoeal Disease Research, Bangladesh (icddr,b). The instrument has seven sections relevant to
the analysis (see S1 File). The first section recorded the respondent’s background information
followed by the respondent’s informed written consent and the relationship with the particular
household. Section 2 gathered the demographic information of household members along
with economic status such as income, expenditure of the households. Section 3 contained the
questions regarding respondent’s perceptions and knowledge about cholera. This section also
discussed how cholera was contracted and their previous experience with cholera. The next
section recorded understanding about vaccine and vaccination in general and about cholera
vaccines in particular. Section 5 introduced the contingent valuation scenario of cholera vac-
cine, including the descriptions of the available Shanchol vaccines, its effectiveness and the
duration of protection. Next some questions were administered in order to test respondent’s
understanding about the effectiveness of proposed vaccine [35,36]. Section 6 contained the val-
uation questions that were used to estimate WTP for OCV for household’s member and for
individual protection against cholera infection. The seventh section recorded interviewer’s
observations on visible conditions of the home and opinions on the quality of the interview.
Data collection and analysis
Data were collected through face-to-face interviews at their households by trained and experi-
enced data collectors. The respondents were either the head of households or the economic
contributor to the family. Data were entered into Microsoft Excel 2007, and all entries were
manually double-checked and verified by the investigators. Before analysis, missing answers
and outliers were systematically verified. Descriptive statistics were employed to analyze and
summarize the data using various variables. Results are presented as a mean and median WTP
with standard deviations and at 95% confidence interval, in Bangladeshi currency
(BDT = Bangladeshi Taka) applying the exchange rate (US$ 1 = BDT 78) during the data
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collection year. Age-specific (under-five, 5 to 14, 15 to 45, 46 to 64 and 65 and above) and
household-specific hypothetical demand was constructed using the proportion of respondent
stating WTP and the amount of WTP for OCV [37,38]. The proportion of population who
expressed the WTP of particular vaccine at the amount indicated used as a proxy of the quan-
tity of vaccines ‘purchased’ at the indicated price [39]. Two econometric models were used in
the analyses; model I was the respondent’s WTP for oral cholera vaccine and model II for the
households WTP of all household members (including respondent). Natural log-linear regres-
sion model was used to examine factors influencing participants’ WTP. The data normality
assumption was tested graphically and the Cook-Weisberg heteroscedasticity test was per-
formed [40]. Power transformation was used to achieve the validity of the assumptions as the
data violate both normality and heteroscedasticity assumptions. In order to obtain a suitable
power transformation of the predicted variables Tukey’s ladder of power was used, from
which the natural log transformation seems to be approximated to achieve the validity of the
assumptions of normality [41]. The Variance Inflation Factor (VIF) was also used to check the
multicollinearity among the predictors. All data analyses were performed using statistical soft-
ware Stata/SE 13 (StataCorp, College Station, TX, USA).
Results
Participants’ characteristics
Background statistics are summarized in Table 1. A total of 1,051 households were surveyed
from the study area at 100% response rate. The average age of the sampled population is about
33 years, most of the respondents were female (80%) and married (93%) Most of the respon-
dents (69%) completed the primary and secondary education and approximately 24% had no
formal schooling, respectively. Average household size was 4.62 persons and approximately
12% and 25% of the households had under-five children and young children aged 5 to 14 years
old, respectively. The average monthly household income was BDT 16,780 (US$ 215.13). The
average healthcare expenditure (last three months) was BDT 4,883 (US$ 62.60). More than
half of the households (59%) shared a rented house while only 17% of respondents had their
own house. Most of the respondents (84%) indicated that the floor of their household was
made of cement and bricks (11%). Only few of them (2%) reportedly lived in soil/mud-based
floor.
Perception and attitude towards cholera and vaccines
Approximately 76% of the respondents mentioned that they heard about cholera infection and
about 80% of the respondents believed that cholera was very serious especially for the under
five children compared to other age groups (Table 2). However, half of the respondents (52%)
were not sure about the risk of cholera in their community. About 29% of the respondents
reported that at least one of the household members had suffered from cholera previously and
1% reported a household member died due to cholera infection. Another 26% of the respon-
dents knew someone other than a household member who had suffered from cholera and 12%
of the total respondents knew someone outside their household who died due to cholera dis-
ease. Almost all of the respondents (90%) had taken at least one vaccine in the past.
Considering the effectiveness of the cholera vaccine, approximately 89% of the respondents
believed that cholera could be prevented by the cholera vaccine while 14% believed that the
cholera vaccine could protect them from risk of death. Of all respondents, 4% believed that
cholera vaccine might reduce their treatment cost and avert sick days (3%) due to cholera
infection. However, 6% were still not sure about the effectiveness of cholera vaccine. After
being given the information and explanation of the OCV effectiveness we tested the
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understanding of the respondents in a structured way [36]. All of the respondents understood
the descriptions of the vaccine effectiveness. Approximately 92% of the respondents gave the
answer correctly to the four questions designed to test the understanding of vaccine
Table 1. Background characteristics of respondents, Dhaka, Bangladesh, 2015–16.
Subject Variables n (%) (95% CI)
Respondent characteristics Sex of the respondent
Male 203 (19.31) (17.04, 21.82)
Female 848 (80.69) (78.18, 82.96)
Age (years)
� 29 449 (42.72) (39.76, 45.74)
30–39 339 (32.25) (29.49, 35.15)
40–49 173 (16.46) (14.34, 18.83)
50 and above 90 (8.56) (7.01, 10.42)
Marital status
Married 980 (93.24) (91.56, 94.61)
Others (unmarried, widow, divorce, separated) 71 (6.76) (5.39, 8.44)
Educational status
No formal education 251 (23.88) (21.40, 26.56)
Primary education 374 (35.59) (32.74, 38.53)
Secondary education 352 (33.49) (30.70, 36.41)
Higher secondary & above 74 (7.04) (5.64, 8.76)
Household characteristics Household size
Less than 4 255 (24.26) (21.76, 26.95)
4 to 5 571 (54.33) (51.30, 57.33)
More than 5 225 (21.41) (19.03, 24.00)
Floor materials
Mud/Soil 14 (1.33) (0.79, 2.24)
Cement 883 (84.02) (81.67, 86.11)
Tiles 18 (1.71) (1.08, 2.70)
Brick 117 (11.13) (9.37, 13.18)
Others 19 (1.81) (1.16, 2.82)
Types of home
Own house 177 (16.84) (14.69, 19.23)
Rented house in slum 126 (11.99) (10.16, 14.10)
Government Residence 12 (1.14) (0.65, 2.00)
Individual separated house, well condition 49 (4.66) (3.54, 6.12)
Rented flat/house (shared with others) 622 (59.18) (56.18, 62.12)
Individual separated house, not well condition 40 (3.81) (2.80, 5.15)
Others 25 (2.38) (1.61, 3.50)
Any healthcare expenditure in last 3 months
Yes 932 (88.68) (86.61, 90.46)
No 119 (11.32) (9.54, 13.39)
Income quintile Mean ± SD (95% CI)
Poorest quintile (�9,000) 245 (23.31) 6,741 ± 1,879 (6,504, 6,977)
2nd quintile (9,001–12,000) 209 (19.89) 10,843 ± 949 (10,713, 10,972)
3rd quintile (12,001–15,000) 206 (19.60) 14,404 ± 830 (14,290, 14,518)
4th quintile (15,001–20,000) 183 (17.41) 18,458 ± 1,577 (18,228, 18,688)
Upper quintile (> 20,000) 208 (19.79) 35,450 ± 24,916 (32,044, 38,856)
https://doi.org/10.1371/journal.pone.0232600.t001
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effectiveness supplementary material. The data collectors explained the vaccine effectiveness
description again and retested to 8% of the respondents who did not answer correctly. Finally,
in total 97% respondents understood the effectiveness concepts after this second attempt.
Willingness to pay for cholera vaccine
WTP values are shown in Table 3. The mean and median WTP for OCV per vaccination (2
doses) was estimated to BDT 174 (US$ 2.23) and BDT 150 (US$ 1.92) respectively for protec-
tion of the respondent against cholera infection. On the household level with an average num-
ber of 4.62 members, the estimated WTP was US $10 (mean) and US$ 7.69 (median) which
represents the perceived private economic benefits to a household of vaccination against chol-
era. Among the total respondents (N = 1,051), approximately 99.4% were WTP for the vac-
cines for their own protection, and 99.8% reported they would purchase the vaccine for their
household members. Financial unaffordability was the main reason for those who did not
agree to pay for oral cholera vaccine. The estimated mean WTP per person for under-five chil-
dren was slightly higher than other age groups (Table 3). Males had a higher WTP than females
Table 2. Perception and attitude towards cholera and cholera vaccine (n = 1,051).
Variables n (%) 95% CI
Heard about cholera
Yes 797 (75.83) (73.15, 78.33)
No 254 (24.17) (21.67, 26.85)
Perceived risk of cholera in community
Not much likely 292 (27.78) (25.15, 30.58)
Likely 189 (17.98) (15.77, 20.43)
Most likely 21 (2.00) (1.31, 3.05)
Don't know/Not sure 549 (52.24) (49.21, 55.25)
Perceived risk of cholera among age groups
0–5 year 405 (80.68) (76.97, 83.91)
6–10 year 33 (6.57) (4.71, 9.11)
11–14 year 8 (1.59) (0.80, 3.16)
15–19 year 8 (1.59) (0.80, 3.16)
20–64 & 65+ year 48 (9.56) (7.27, 12.47)
Perceived severity of cholera among age group (0–5) year (multiple response)
Very severe 96 (23.70) (19.75, 28.04)
Severe 91 (22.47) (18.83, 27.01)
Not very severe 193 (47.65) (42.70, 52.42)
Don't know/Not sure 25 (6.17) (4.19, 8.97)
Someone in household has had cholera
Yes 307 (29.21) (26.53, 32.04)
No 744 (70.79) (67.96, 73.47)
Someone in household had died having cholera
Yes 11 (1.05) (0.58, 1.88)
No 1040 (98.95) (98.12, 99.42)
Know someone who has had cholera (outside households)
Yes 278 (26.45) (23.87, 29.21)
No 773 (73.55) (70.79, 76.13)
Know someone who has died having cholera (outside households)
Yes 128 (12.18) (10.33, 14.30)
No 923 (87.82) (85.70, 89.67)
https://doi.org/10.1371/journal.pone.0232600.t002
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(BDT 176.98 or US$ 2.27 vs BDT 170.87 or US$ 2.19). A general socioeconomic gradient was
observed in WTP, meaning that the richer socioeconomic groups were WTP more, with a
slight exception in the 4th quintile.
Household demand for OCV
The age-specific demand and household demand for OCV have been illustrated in Fig 1 and
Fig 2 respectively. We found that the hypothetical demand for cholera vaccine is slightly higher
Table 3. Household’s willingness to pay for future cholera vaccine Dhaka, Bangladesh, 2015–16.
Variables n Mean WTP ± SD Median Interquartile range IQR 5th percentile 95th percentile P-value
Age groups
Up to 4 579 182.76 ± 133.89 150 100 50 400 0.125
5 to 14 1,200 168.86 ± 129.53 150 100 50 400
15 to 45 2,455 176.13 ± 135.91 150 100 50 400
46 to 64 370 164.62 ± 115.96 125 100 50 400
65 and above 109 166.61 ± 111.94 150 100 50 400
Sex
Male 2,392 176.98 ± 139.33 150 120 50 400 0.056
Female 2,321 170.87 ± 124.20 150 100 50 400
Income quintile
Poorest quintile (� 9,000) 949 152.19 ± 92.27 130 100 40 300 0.000
2nd quintile (9.001–12,000) 1,016 160.43 ± 158.02 128 100 50 300
3rd quintile (12,001–15,000) 867 173.45 ± 111.95 150 120 50 350
4th quintile (15,001–20,000) 965 171.60 ± 121.85 150 100 50 500
Upper quintile (20,000+) 916 214.55 ± 153.36 200 200 50 500
Household size
Less than 4 759 199.44 ± 181.12 150 150 50 400 0.000
4 to 5 2,455 169.86 ± 121.45 150 100 50 400
More than 5 1,499 167.81 ± 117.27 125 100 50 400
Household WTP, BDT 1,049 781.62 ± 631.99 600 550 190 2,000
Per capita WTP per OCV, BDT 4,713 173.97 ± 132.12 150 100 50 400
�BDT = Bangladeshi Taka � OCV = Oral Cholera vaccine
https://doi.org/10.1371/journal.pone.0232600.t003
Fig 1. Age-specific demand for OCV, Dhaka, Bangladesh, 2015–16.
https://doi.org/10.1371/journal.pone.0232600.g001
PLOS ONE Willingness to pay for oral cholera vaccines
PLOS ONE | https://doi.org/10.1371/journal.pone.0232600 April 30, 2020 8 / 16
for under-five children than people at age 15 years and above. The demand curve shows the
share of households at different levels of WTP for people at different ages (Fig 1).
Fig 2 shows a negative relationship between WTP and the proportion of households WTP
those specific amounts meaning that higher proportion of households are willing to pay at
lower level of vaccine price. At the current market price of US$ 9.24 for vaccinating an entire
household, 50% households would prefer to vaccinate themselves (Fig 2).
Factors associated with the willingness to pay
In Table 4, the natural log-linear regression model revealed that a number of factors were signif-
icantly associated with the respondent’s WTP for protecting him-/herself and all household
members from cholera infection. The factors are sex of the respondents, his/her occupation,
knowledge about cholera and oral cholera vaccine, household income, size of the households
and age composition of household members. Considering the sex of the respondents, males had
significantly higher WTP than females and were willing to pay 15% more for himself and
approximately 18% more for their households (Table 4). The employed respondents reported
lower amount of WTP than unemployed. Those who were exposed for cholera in past, intended
to pay more for themselves and the household (9.4% and 10.5% respectively) than those who
did not have such experience. We observed that WTP was higher in the households where the
number of under-five children, children aged 5 to 14 years and number of adult household
members in the household increases. One under-five child will lead to 15% more WTP for
household and 7.2% and 8.3% more for children aged 5–14 years and adults (>14 years) respec-
tively. The size of the households is one of the significant negative factors on respondent WTP
and larger households were negatively associated with WTP. Household with 4 to 5 members
had 11.6% less WTP for respondent compared with smaller household (<4 members).
Our model showed that household income was significantly positively associated with the
both respondent’s and household’s WTP. Respondents from higher income households are
willing to pay more compared to respondents from lower income households for their own
protection as well as for their household protection. For own protection, respondents from the
3rd, 4th and 5th quintiles were willing to pay 18.5% (p<0.05), 16.1% (p<0.05), and 43.3%
(p<0.001) more compared to respondents from lower income households (poorest quintile).
Considering the household protection against future cholera cases, it was observed that the 3rd,
4th, and 5th quintile’s WTP were 22.1% (p<0.001), 18.5% (p<0.05), and 46.2% (p<0.001)
more than the poorest quintile.
Fig 2. Household demand for OCV, Dhaka, Bangladesh, 2015–16.
https://doi.org/10.1371/journal.pone.0232600.g002
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Discussion
The study was conducted in order to assess the average maximum WTP for a future cholera
vaccine and its associated determinants among the household heads and their household
members in an urban area of Bangladesh. Our study found that the per capita maximum WTP
Table 4. Factors influencing on willingness-to-pay (WTP as a natural log form) for oral cholera vaccine, Dhaka, Bangladesh, 2015–16.
Parameters Descriptions Co-efficient (Standard Error)
Respondents’ WTP Households’ WTP (including respondent)
Age of respondent (years)
30–39 Ref: Less than 30 years -0.01 (0.05) 0.03 (0.05)
40–49 -0.04 (0.07) 0.00 (0.07)
50 and above -0.11 (0.09) -0.08 (0.09)
Sex of respondent
Male Ref: Female 0.15�� (0.07) 0.18�� (0.07)
Respondent educational status
No formal education Ref: Higher secondary & above -0.04 (0.09) -0.05 (0.09)
Primary education 0.01 (0.08) 0.05 (0.09)
Secondary education 0.05 (0.08) 0.09 (0.08)
Respondent Occupation
Employed Ref: Unemployed -0.12�� (0.06) -0.12�� (0.06)
Other variables
Received any vaccine Ref: Yes 0.01 (0.07) -0.02 (0.07)
Someone in household has had cholera Ref: Yes 0.09�� (0.04) 0.10�� (0.05)
Someone in household had died having cholera Ref: Yes 0.29 (0.20) 0.26 (0.20)
Know someone has had cholera (outside HH) Ref: Yes 0.14��� (0.05) 0.16��� (0.05)
Heard about cholera Ref: Yes 0.05 (0.05) 0.03 (0.05)
Cholera is common in community Ref: Yes 0.01 (0.07) -0.02 (0.07)
Child (<5 years) is more vulnerable for cholera Ref: Yes -0.04 (0.07) -0.05 (0.07)
Healthcare Utilization Ref: Yes 0.04 (0.06) 0.05 (0.06)
Number of U5 children Continuous 0.03 (0.04) 0.14��� (0.04)
Number of child age 5 to 14 Continuous -0.03 (0.03) 0.07�� (0.03)
Number of adult members (>14 years) Continuous -0.04 (0.03) 0.08��� (0.03)
Household size
4 to 5 Ref: Less than 4 members -0.11 (0.06) 0.08 (0.06)
More than 5 -0.14 (0.11) 0.15 (0.11)
Income quintile (BDT)
2nd quintile Ref: 1st/Poorest quintile 0.05 (0.06) 0.05 (0.06)
3rd quintile 0.17��(0.06) 0.20��� (0.06)
4th quintile 0.15�� (0.07) 0.17�� (0.07)
Upper quintile 0.36��� (0.07) 0.38��� (0.07)
Intercept Constant 5.30��� (0.15) 6.07��� (0.15)
N 1,045 1,049
Adjusted R-square 0.054 0.164
Mean VIF 2.23 2.23
F-value, (Prob > F) 3.38��� 9.20���
���significant at 1% risk level
��significant at 5% risk level
#Percentage change of WTP explained by (eβ-1)�100
https://doi.org/10.1371/journal.pone.0232600.t004
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was BDT 174 (US$ 2.23) for OCV use against cholera disease. On the household level, each
household was ready to invest BDT 782 (US$ 10.02) for purchasing the cholera vaccine to pro-
tect their members from cholera cases.
The study demonstrated that most of the respondents (98%) reported their willingness to
purchase OCV for the protection of their own and their household members if financially
affordable. WTP was found to be higher (98%) in urban areas in comparison with rural areas
of Bangladesh as found in another study, where 75% of the responded of the rural residents
were interested in OCV [33]. Such difference between urban and rural areas could be
explained by the disparity of financial affordability between urban and rural people where the
former were better-off. However, since Bangladesh has recently been upgraded as a lower-
middle income country and poverty has declined substantially, we may expect more people,
also in rural areas, to be interested to purchase OCV than in the past [42]. Our estimation sup-
ported that the households with members of age under five years were willing to pay more
than any other age groups. Such findings were also observed in the rural context in Bangladesh
[33]. Since it was observed that the young children were more vulnerable to cholera in Bangla-
desh, higher demand of OCV was thus expected [3]. Considering the current market price of
OCV (US$ 2.00), the vaccination coverage is higher for under-five children (68%) than age 15
years and above. From the experience of an earlier study conducted in this setting, it was
observed that the household invested more money on cholera infected children than adult
members for seeking treatment [6].
Our log-linear regression model suggested that the male respondents had significantly
higher WTP than the females, which was in line with findings of other studies as male often
predominantly deal with the financial matters including healthcare expenditure of the house-
hold [33,43,44]. However, such relationship was not always observed [45].It was further
revealed that the respondents with past experience in cholera and cholera-related deaths
expressed higher WTP both for self-protection and protection of the household members.
This finding was supported by earlier studies which indicated that the household risk aversion
is a crucial influencing factor for demand for future OCV [33,46]. However, on the contrary,
there were evidence that prior awareness of disease or having a personal history of a disease
did not always lead to higher WTP [47–50]. Unlike other study, we observed that employed
respondents reported lower WTP than unemployed person as income earner appeared to be
much concerned about other household expenditure [51]. Therefore, further research on this
topic should be required in order to provide a better explanation. Household income signifi-
cantly positively affected both respondent’s and household’s WTP which was consistent with
the theoretical concept of positive income elasticity that wealthier families purchase more chol-
era vaccines than low-income households [33,46,52]. This was crucial for policy implication in
Bangladesh where 67% of total healthcare expenditures were borne by out-of-pocket payments
in absence of social health insurance and the poor people were often unable to afford adequate
healthcare [53].
A free-of-cost supply of OCV to a typical member of the population in this study would
bring a perceived economic benefit of 781.6 BDT corresponding to the average WTP of the
households. In an earlier study, we found that full vaccination of an individual cost BDT
165.36 (US$ 2.12) which included freight charge, transportation and imported price of vials
[54]. The individual WTP for OCV (BDT 174 or US$ 2.23), observed in this current study,
exceeded the costs of vaccination, which indicated the economic viability of OCV in a market
condition. It could be argued that the delivery costs of OCV would increase the vaccination
costs [54]. Such additional costs could be covered by an incremental cost to the EPI program
of Bangladesh, funded preferably by pooled fund (e.g., taxes).
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Recently a well-known pharmaceutical company indicated that the production of the chol-
era vaccine might be possible at a cost below BDT 78 (US$ 1) in Bangladesh [55]. Considering
such a statement, we calculated the total costs of vaccinating a household to be BDT 720 (US$
9.23) at which price approximately 50% of the households of Bangladesh would be able to pur-
chase OCV from private market. For the full coverage of OCV in the country, pooled fund
(e.g., taxes) could be additionally used for subsidizing the households with lower maximum
WTP. It was also observed that, even at higher vaccine prices, there was demand for OCV
among the wealthier households. Indeed, the poor people would be also benefit from vaccina-
tion of wealthier populations because of herd immunity [33,56]. Based on the economic condi-
tion of the country and demand for OCV as per our current study, we recommend that a
sustainable financing method could be developed where pooled fund such as tax and revenue
from sold vaccines in private market would be used jointly.
There are some limitations of the current study that need to be considered in interpreting
the results. In applying contingent valuation techniques, a possible source of bias might arise
from the fact that respondents are not purchasing the vaccine in the practical context but
rather hypothetically [57]. Again due to resource constraints we did not introduce time-to-
think approach [33]. Further, we did not introduce herd immunity in contingent valuation
scenario, so our results underestimate the true value of this particular vaccine. We did not vali-
date the demand for OCV using the travel cost approach where earlier studies indicated that
the private demand for OCV was low because of household cost such as transportation and
time cost was incurred due to receiving the vaccine [58]. All of the above represent possible
avenues for further research on this topic.
Conclusions
Our research provided evidence on the perceived demand for OCV, suggesting that the house-
holds may not wait for the public vaccination campaign, but rather can protect themselves
from cholera if the vaccine is available in private market. The demand for vaccination further
indicates that there is a potential scope for recovering a certain portion of the expenditure of
immunization program by introducing direct user fees for future cholera vaccination in Ban-
gladesh. A combination of funding from revenue of private market and pooled fund (e.g.,
taxes) could be considered as a sustainable way of financing oral cholera vaccine in Bangladesh
to secure protection against cholera.
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